PMCB · XBRL financial data

PharmaCyte Biotech financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PMCB's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022†Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Revenue	0	0	0	0	0	0
Research and development	916	691	469	407	438	391
General and administrative	418	1,090	1,113	2,117	3,939	4,913
Total operating expenses	3,623	4,392	6,455	8,520	4,378	6,854
Operating income (loss)	(3,623)	(4,392)	(6,455)	(8,520)	(4,378)	(6,854)
Interest expense	3	1	0	—	—	—
Other income (expense)	72	(4)	202	191	(1)	(1)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(3,551)	(4,239)	(4,316)	334	30,656	(19,425)
Earnings per share, basic USD per share	(2.45)	(0.27)	(0.22)	(1.80)	3.19	(2.77)
Earnings per share, diluted USD per share	(2.45)	(0.27)	(0.22)	(1.80)	3.19	(2.77)
Weighted average shares, basic thousands of shares	1,448	15,522	19,489	9,581	7,330	8,378
Weighted average shares, diluted thousands of shares	1,448	15,522	19,489	9,581	7,330	8,378

† Share count changed about 13x in the period ending 2022-04-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PMCB's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022†Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Cash and cash equivalents	2,202	85,401	68,040	50,180	15,172	18,604
Marketable securities	—	—	—	0	366	254
Prepaid and other current assets	73	94	108	260	224	97
Total current assets	2,275	85,495	68,148	50,440	22,375	37,421
Total assets	7,404	90,624	73,277	59,904	55,168	46,753
Accounts payable	172	205	128	389	399	271
Accrued liabilities	553	499	458	735	2,515	523
Total current liabilities	725	704	587	7,421	2,914	826
Total liabilities	725	704	587	20,389	3,277	11,772
Accumulated deficit	(107,409)	(111,649)	(115,959)	(115,625)	(84,969)	(104,394)
Total stockholders' equity	6,679	89,920	72,690	27,648	51,891	33,295
Total liabilities and equity	7,404	90,624	73,277	59,904	55,168	46,753
Common shares outstanding (cover page) thousands of shares	1,612	20,749	8,778	7,709	6,796	10,736

† Share count changed about 13x in the period ending 2022-04-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PMCB's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022†Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Net income (loss)	(3,551)	(4,239)	(4,316)	334	30,656	(19,425)
Stock-based compensation	194	33	7	0	479	893
Net cash from operating activities	(3,331)	(4,117)	(3,794)	(2,151)	(2,978)	(5,153)
Net cash from investing activities	0	0	0	(5,000)	(7,000)	2,000
Proceeds from issuing common stock	4,699	87,362	0	—	—	—
Share repurchases	—	0	13,561	28,198	2,542	402
Net cash from financing activities	4,637	87,311	(13,560)	(10,708)	(25,029)	6,582
Net change in cash	1,307	83,199	(17,361)	(17,860)	(35,008)	3,432

† Share count changed about 13x in the period ending 2022-04-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.